Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chiron withdraws MMR vaccine
The company supplied approximately five million doses of Morupar vaccine in 2005, providing most of its production to a limited number of developing countries, largely via the United
The company supplied approximately five million doses of Morupar vaccine in 2005, providing most of its production to a limited number of developing countries, largely via the United
The open label dose finding study, dubbed XACT, involves dosing of AMD070 twice daily for 10 consecutive days. There are up to 4 cohorts with a total of
Upon closing of the transaction, Hana will pay Inex $11.5 million in an upfront payment, consisting of cash and Hana shares. Inex will receive an additional $30.5 million
The amended protocol now includes a higher dose and increases the number of patients targeted for enrollment from 40 to 120. Under the amended protocol, the study is
Pradefovir is a pro-drug of adefovir that was licensed from Metabasis Therapeutics. Pradefovir uses Metabasis’ HepDirect technology which enables higher concentrations of the drug in the liver, the
The company’s siRNAs are specifically designed to target conserved regions of the influenza viral genome which could enable a siRNA therapeutic to be effective against both current and
Scientists from the University of California and Stanford University looked at the use of the statin Lipitor in combination with Teva Pharmaceutical’s Copaxone, a drug already approved for
Rituxan is normally used to treat lymphoma, rheumatoid arthritis and other immune disorders. “If the drug is effective, it could help prevent some of the long-term complications that
Oxycyte is Synthetic Blood’s proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute. The formulation will be investigated in eight patients with severe traumatic brain injury. “We are
The patent claims cover methods of treating a variety of diseases with 2-methoxyestradiol (2ME2), including solid tumors or tumor metastases, and immune and inflammatory diseases. The patent is